Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumors 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 59Carboplatin 56Pemetrexed 47Cisplatin 39Paclitaxel 24Nivolumab 23Docetaxel 21durvalumab 20Gemcitabine 15130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 8Radiotherapy 8Radiosurgery 7Ipilimumab 7lazertinib 6alectinib 6Ramucirumab 6Observation 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5Etoposide 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × adagrasib × 30 days × Clear all
NCT06764771 2026-06-03

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Bristol-Myers Squibb

Phase 1 Recruiting
437 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT06875310 2026-06-02

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Mirati Therapeutics Inc.

Phase 3 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04613596 2026-05-20

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mirati Therapeutics Inc.

Phase 2/3 Recruiting
626 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡